Galina Statsenko

6.8k total citations
25 papers, 238 citations indexed

About

Galina Statsenko is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Galina Statsenko has authored 25 papers receiving a total of 238 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in Galina Statsenko's work include Lung Cancer Research Studies (11 papers), Fibroblast Growth Factor Research (6 papers) and Cancer therapeutics and mechanisms (5 papers). Galina Statsenko is often cited by papers focused on Lung Cancer Research Studies (11 papers), Fibroblast Growth Factor Research (6 papers) and Cancer therapeutics and mechanisms (5 papers). Galina Statsenko collaborates with scholars based in Russia, United States and United Kingdom. Galina Statsenko's co-authors include Mustafa Özgüroğlu, Niels Reinmuth, Jun Ho Ji, Jonathan W. Goldman, Katsuyuki Hotta, Maximilian J. Hochmair, Luis Paz‐Ares, Libor Havel, Dmytro Trukhin and Олександр Войтко and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Galina Statsenko

25 papers receiving 232 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Galina Statsenko Russia	9	200	149	85	75	15	25	238
Kim Norris United States	3	219 1.1×	182 1.2×	100 1.2×	55 0.7×	8 0.5×	8	249
V. Westeel France	8	262 1.3×	114 0.8×	205 2.4×	85 1.1×	4 0.3×	20	334
S. Morris Switzerland	7	243 1.2×	93 0.6×	123 1.4×	53 0.7×	8 0.5×	13	267
María Ángeles Sala Spain	6	124 0.6×	76 0.5×	66 0.8×	27 0.4×	7 0.5×	24	174
Philip Clingan Australia	5	238 1.2×	195 1.3×	58 0.7×	115 1.5×	32 2.1×	8	282
Hamzeh Albaba Canada	6	113 0.6×	38 0.3×	67 0.8×	17 0.2×	17 1.1×	11	152
Jonathan Macni Martinique	8	109 0.5×	46 0.3×	44 0.5×	32 0.4×	32 2.1×	22	192
José Antonio López-Vilariño Spain	7	133 0.7×	83 0.6×	44 0.5×	83 1.1×	6 0.4×	21	184
Stephan Bildat Germany	6	208 1.0×	118 0.8×	138 1.6×	121 1.6×	16 1.1×	11	301
O. Molinier France	9	216 1.1×	26 0.2×	247 2.9×	39 0.5×	14 0.9×	20	296

Countries citing papers authored by Galina Statsenko

Since Specialization

Citations

This map shows the geographic impact of Galina Statsenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Galina Statsenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Galina Statsenko more than expected).

Fields of papers citing papers by Galina Statsenko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Galina Statsenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Galina Statsenko. The network helps show where Galina Statsenko may publish in the future.

Co-authorship network of co-authors of Galina Statsenko

This figure shows the co-authorship network connecting the top 25 collaborators of Galina Statsenko. A scholar is included among the top collaborators of Galina Statsenko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Galina Statsenko. Galina Statsenko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tsimafeyeu, Ilya, et al.. (2023). A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated advanced gastric cancer. Investigational New Drugs. 41(2). 324–332. 6 indexed citations

Statsenko, Galina, et al.. (2023). Approaches to the diagnosis and treatment of patients with stage III—IV non-small cell lung cancer in Russia. Preliminary results of a prospective multicenter non-interventional observational study KARL. P A Herzen Journal of Oncology. 12(6). 33–33. 1 indexed citations

Chen, Yuanbin, Luis Paz‐Ares, Niels Reinmuth, et al.. (2022). Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report. JTO Clinical and Research Reports. 3(6). 100330–100330. 27 indexed citations

Statsenko, Galina, et al.. (2022). 45P Alofanib in subsequent therapy of advanced gastric cancer: Final results from the phase Ib clinical trial. Annals of Oncology. 33. S20–S20. 1 indexed citations

Reinmuth, Niels, M.C. Garassino, Yuanbin Chen, et al.. (2022). 141O Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: Characteristics of long-term survivors in the CASPIAN study. Annals of Oncology. 33. S97–S98. 3 indexed citations

Tsimafeyeu, Ilya, et al.. (2022). Alofanib in subsequent therapy for advanced gastric cancer: Final results from the phase Ib clinical trial.. Journal of Clinical Oncology. 40(16_suppl). e16077–e16077. 1 indexed citations

Statsenko, Galina, et al.. (2022). Abstract 3481: Pharmacokinetics of alofanib and biomarker analysis in patients with advanced gastric cancer: A phase 1b study. Cancer Research. 82(12_Supplement). 3481–3481. 2 indexed citations

Tsimafeyeu, Ilya, et al.. (2021). Survival of patients with metastatic bladder cancer in the Russian Federation: results of a multicenter registry study URRU. SHILAP Revista de lepidopterología. 17(3). 102–109. 3 indexed citations

Paz‐Ares, Luis, Yuanbin Chen, Niels Reinmuth, et al.. (2021). LBA61 Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study. Annals of Oncology. 32. S1338–S1338. 8 indexed citations

10.

Зуков, Р. А., et al.. (2021). The association of access to systemic therapy and overall survival in metastatic bladder cancer in Russia: An analysis of URRU register.. Journal of Clinical Oncology. 39(28_suppl). 88–88. 1 indexed citations

11.

Goldman, Jonathan W., Marina Chiara Garassino, Yuanbin Chen, et al.. (2020). LBA86 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN. Annals of Oncology. 31. S1212–S1213. 17 indexed citations

12.

Goldman, Jonathan W., Marina Chiara Garassino, Yuanbin Chen, et al.. (2020). 379MO Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN. Annals of Oncology. 31. S1388–S1389. 2 indexed citations

13.

Chen, Yuanbin, Luis Paz‐Ares, Mikhail Dvorkin, et al.. (2020). First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes.. Journal of Clinical Oncology. 38(15_suppl). 9068–9068. 12 indexed citations

14.

Paz‐Ares, Luis, Mikhail Dvorkin, Yuanbin Chen, et al.. (2020). Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.. Journal of Clinical Oncology. 38(15_suppl). 9002–9002. 33 indexed citations

15.

Statsenko, Galina, et al.. (2020). A phase Ib study of alofanib, an allosteric FGFR2 inhibitor, in patients with advanced or metastatic gastric cancer.. Journal of Clinical Oncology. 38(4_suppl). TPS466–TPS466. 2 indexed citations

16.

Goldman, Jonathan W., Marina Chiara Garassino, Yuanbin Chen, et al.. (2020). Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study. Lung Cancer. 149. 46–52. 31 indexed citations

17.

Özgüroğlu, Mustafa, Jonathan W. Goldman, Niels Reinmuth, et al.. (2019). LBA2 First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: Safety, pharmacokinetics (PK) and immunogenicity in CASPIAN. Annals of Oncology. 30. xi66–xi66. 2 indexed citations

18.

Paz‐Ares, Luis, Jonathan W. Goldman, Marina Chiara Garassino, et al.. (2019). PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN. Annals of Oncology. 30. v928–v929. 39 indexed citations

19.

Tsimafeyeu, Ilya, Sergei Varlamov, Р. А. Зуков, et al.. (2017). Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry. Clinical Genitourinary Cancer. 15(6). e1069–e1072. 25 indexed citations

20.

Tyulyandina, Alexandra, Vera Gorbunova, Л. А. Коломиец, et al.. (2017). Comprehensive analysis of germline and somatic BRCA1/2 mutations in ovarian cancer population: Interim results of OVATAR prospective study.. Journal of Clinical Oncology. 35(15_suppl). e23109–e23109. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact